Post-earnings recap
Reported
Wed, Aug 9, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising 1.5%. While revenue figures were not disclosed, management's focus on clinical trials suggests they are prioritizing long-term growth. Investors may view the EPS beat as a sign of potential future profitability.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -0.45 | N/A | +4.47% |
| Revenue | N/A | N/A | N/A |
Management remains cautiously optimistic about the company's future. They emphasized their commitment to advancing their clinical programs.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They highlighted ongoing efforts in their clinical trials and future product pipeline.